30 Prime-supported Medicare contracts earn quality bonuses

92% of Prime-supported Medicare Advantage members will be in contracts that earned a quality bonus payment from CMS

November 16, 2021

Prime Therapeutics (Prime) helped 30 of its Medicare Advantage Prescription Drug (MAPD) contracts, representing 92% of MAPD membership, receive a quality bonus payment for earning four stars or more in the ratings released by the Centers for Medicare and Medicaid Services (CMS). This includes five contracts that achieved a 5-Star overall rating, and 10 new contracts that earned a quality bonus payment compared to last year.

Stars and total drug management

As a pharmacy benefit manager, Prime influences many of the Star rating measures across:

  • Operations
  • Customer experience
  • Medication adherence and clinical management

Prime helped improve our plans’ ratings for Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys, which are highly weighted measures in determining overall ratings. These member surveys include an overall rating of the drug plan, and how easy it is for the member to get needed prescriptions.

“These ratings show that Prime is contributing to improving the quality of health care, while at the same time making health care more affordable and accessible to Medicare members,” says Kim Kishel-Geiger, senior director, quality management. “Each year favorable ratings become more difficult to achieve because the bar is continually raised, so we must continue to be innovative.”

Related news

Stories

May 15, 2024

Prime/MRx experts share clinical insights for migraine treatment

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

Stories

May 14, 2024

Prime/MRx real-world GLP-1 persistence and adherence data published in Journal of Managed Care & Specialty Pharmacy

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

Stories

May 14, 2024

Prime/MRx releases its first corporate social responsibility report

New report, an evolution of previous DEI reports, aims to demonstrate transparency and accountability for company’s corporate social responsibility journey